Calidi Biotherapeutics (CLDI) vs Jupiter Neurosciences (JUNS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Calidi Biotherapeutics is the larger company by market cap ($3.8 million vs $3.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | JUNS |
|---|---|---|
| Share price | $1.04 | $2.77 |
| Market cap | $3.82M | $3.65M |
| 1-day change | +2.97% | -2.46% |
| Forward P/E | — | 46.17 |
| EPS (TTM) | $-36.47 | $-18.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $135.75 |
| 52-week low | $0.986 | $2.25 |
| Distance from 52-week high | -96.26% | -97.96% |
| Average volume | 255.53K | 983.10K |
| Shares outstanding | 3.68M | 1.32M |
| Employees | 29 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Healthcare · Biotechnology · 29 employees
About Jupiter Neurosciences
JUNS stock →Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.
Healthcare · Biotechnology · 5 employees
CLDI vs JUNS FAQ
Which is bigger, Calidi Biotherapeutics or Jupiter Neurosciences?
Calidi Biotherapeutics (CLDI) is larger, with a market capitalization of $3.82M compared with $3.65M for Jupiter Neurosciences (JUNS).
Are Calidi Biotherapeutics and Jupiter Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.